P
Paul J. Orchard
Researcher at University of Minnesota
Publications - 259
Citations - 14759
Paul J. Orchard is an academic researcher from University of Minnesota. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 48, co-authored 229 publications receiving 12985 citations. Previous affiliations of Paul J. Orchard include University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Successful donor engraftment and repair of the blood-brain barrier in cerebral adrenoleukodystrophy.
Paul J. Orchard,David Nascene,Weston P. Miller,Ashish Gupta,Daniel L. Kenney-Jung,Troy C. Lund +5 more
TL;DR: The data suggest that robust donor myeloid recovery is necessary for timely repair of the blood-brain barrier (BBB) disruption and an active inflammatory disease process inrenoleukodystrophy.
Journal ArticleDOI
Population Pharmacokinetics of Unbound Mycophenolic Acid in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Hyewon Kim,Janel Long-Boyle,Nancy Rydholm,Paul J. Orchard,Jakub Tolar,Angela R. Smith,Pamala A. Jacobson,Richard C. Brundage +7 more
TL;DR: In alloHCT recipients with renal dysfunction or severe hepatic injury, dose reductions may be necessary to prevent toxicity and ensure optimal immunosuppression.
Journal ArticleDOI
The Minnesota Molecular and Cellular Therapeutics Facility: a state-of-the-art biotherapeutics engineering laboratory.
David H. McKenna,Diane Kadidlo,Jeffrey S. Miller,Paul J. Orchard,John E. Wagner,Jeffrey McCullough +5 more
TL;DR: An overview of the Minnesota Molecular and Cellular Therapeutics (MMCT) Facility is provided, detailing the approach to the manufacture of novel therapeutics and highlighting current and future activities.
Journal ArticleDOI
Haploidentical Transplantation With Post-Transplant Cyclophosphamide Following Reduced-Intensity Conditioning for Osteopetrosis: Outcomes in Three Children
TL;DR: Haploidentical transplantation with post-transplant cyclophosphamide following reduced-intensity conditioning for osteopetrosis with positive outcomes in three children.
Journal ArticleDOI
Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I.
Lalitha R. Belur,Megan Romero,Junggu Lee,Kelly M. Podetz-Pedersen,Zhenhong Nan,Maureen S. Riedl,Lucy Vulchanova,Kelley F. Kitto,Carolyn A. Fairbanks,Karen Kozarsky,Paul J. Orchard,William H. Frey,Walter C. Low,R. Scott McIvor +13 more
TL;DR: In this article, the authors investigated the effectiveness of AAV-mediated IDUA gene delivery to the brain using several different routes of administration, including direct intracerebroventricular (ICV) injection, intrathecal (IT) infusion into the cerebrospinal fluid, or by intranasal (IN) instillation of a AAV9-IDUA vector.